Jun 1, 2021
NCT04855929: Phase 1: Safety and Therapeutic Activity of ANV419 in RRMM - ANV419-001
NCT04855929: Phase 1: A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer and Multiple Myeloma....
30
top of page
Posts Archive
bottom of page